| Drug Name |
Migalastat |
| Drug ID |
BADD_D02572 |
| Description |
Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A) [FDA Label, F1107, L4274, L4263]. This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other organs [FDA Label, F1107, L4274, L4278]. In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated [L4274].
Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who have amenable GLA variants [FDA Label, F1107, L4274, L4278]. In these patients, migalastat works by stabilizing the body’s own dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate [FDA Label, F1107, L4274, L4278]. Globally, it is estimated that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants that are treatable with migalastat [L4274].
Given the rarity of Fabry disease and the proportion of Fabry disease patients that could benefit from migalastat therapy, Amicus Therapeutics' brand name Galafold was approved using the Accelerated Approval pathway, under which the FDA may approve drugs for serious conditions where there is an unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients [FDA Label, F1107, L4274, L4278]. A further study is required to verify and describe the clinical benefits of Galafold, and the sponsor will be conducting a confirmatory clinical trial of Galafold in adults with Fabry disease [FDA Label, F1107, L4274, L4278].
Additionally, Galafold was alzo granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines that the drug, if approved, would provide a significant improvement in treating, diagnosing or preventing a serious condition over available therapies [FDA Label, F1107]. Galafold also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases [FDA Label, F1107].
As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and the United States. |
| Indications and Usage |
Migalastat is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone indicated for the long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and an amenable galactosidase alpha gene (GLA) mutation/variant based upon in vitro assay data [FDA Label, F1107].
This indication is approved by the US FDA under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate [FDA Label]. Continued approval by the US FDA for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AX14 |
| DrugBank ID |
DB05018
|
| KEGG ID |
D10359
|
| MeSH ID |
C090092
|
| PubChem ID |
176077
|
| TTD Drug ID |
D0MU9L
|
| NDC Product Code |
Not Available |
| UNII |
C4XNY919FW
|
| Synonyms |
migalastat | AT1001 deoxyjirimycin | GR181413A | Galafold | N-butyldeoxygalacto-nojirimycin | NB-DGJ | N-butyldeoxygalactonojirimycin | 1-butyl-2-(hydroxylmethyl)piperidine-3,4,5-triol | lucerastat | 1-deoxy-galactonojirimycin | 1-deoxygalactonojirimycin | 1-deoxygalacto-nojirimycin | migalastat hydrochloride | migalastat HCl |
